The story of kratom regulation in the United States over the past decade is unusual. A botanical that the DEA proposed to schedule as Schedule I in 2016 is, today, legally available in most states — not because regulators concluded it was safe, but because organised consumer advocacy and credible scientific testimony pushed back hard enough that the proposal was withdrawn. The years since have produced a patchwork of state-level regulation that, while imperfect, represents one of the more interesting recent examples of citizen-driven drug policy.

This article is a brief tour of what’s happened, who made it happen, and what’s still being worked on.

The 2016 DEA reversal

In August 2016, the Drug Enforcement Administration announced its intent to use emergency scheduling authority to place mitragynine and 7-hydroxymitragynine in Schedule I — the most restrictive category, reserved for substances with “no currently accepted medical use” and “high potential for abuse.” Schedule I status would have effectively ended legal kratom in the United States and made research significantly harder.

What followed was unexpected. Within weeks:

  • A petition opposing the scheduling gathered more than 140,000 signatures
  • 51 members of Congress signed a letter to the DEA urging reconsideration
  • 9 senators signed a similar letter
  • Researchers and clinicians submitted public comments raising concerns about both the underlying science and the procedural use of emergency scheduling
  • The American Kratom Association coordinated much of the response, alongside individual consumer advocates

In October 2016, the DEA withdrew its notice of intent and opened a public comment period instead — an unusual reversal. Schedule I status has not been revisited since at the federal level.

The Kratom Consumer Protection Act

The federal stalemate left a regulatory gap: kratom was effectively legal at the federal level, but with no labelling, testing, or quality requirements. Consumer advocates pivoted to state-level legislation. The vehicle was a model bill called the Kratom Consumer Protection Act (KCPA).

The KCPA generally requires:

  • Age restriction (typically 18 or 21) for kratom purchases
  • Mandatory product testing for contaminants and alkaloid content
  • Labelling requirements: ingredients, alkaloid concentrations, manufacturer information
  • Prohibition on adulterated or synthetic products mixed with controlled substances
  • Penalties for vendors selling non-compliant products

The model is consumer-protection regulation rather than prohibition: kratom remains legally available, but vendors must meet quality standards and consumers get the labelling information they need to make informed choices.

State-by-state passages

Since 2019, KCPA-modelled legislation has passed in a steadily growing number of states. The list now includes (among others) Utah, Georgia, Arizona, Nevada, Oregon, Oklahoma, Colorado, Mississippi, Texas, Florida, Virginia, West Virginia, Maryland, Missouri, and others. Specific provisions vary state by state — some include felony penalties for selling adulterated products; some focus more narrowly on labelling and testing.

For the live state-by-state status of both KCPA legislation and broader kratom legality, the state-by-state guide is the authoritative current view. The list above is a snapshot, not a current legal reference.

Where kratom is still banned

A small number of states have banned kratom outright at various points: Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin, and the District of Columbia have all had bans in place at some point in the past decade. Some of these bans have been challenged or modified; others remain. Several large cities have also enacted local bans even where the surrounding state permits kratom.

The pattern: bans tend to happen in jurisdictions where well-organised consumer advocacy was absent or arrived after the legislative process was already underway. Where consumer advocates and the AKA engaged early, the result has more often been KCPA-style regulation rather than prohibition.

Who actually did the work

The organised side of kratom advocacy in the US has run primarily through the American Kratom Association (AKA), a 501(c)(4) consumer advocacy organisation founded in 2014. The AKA coordinates lobbying, runs the GMP qualification programme for vendors, supports research funding, and tracks state-level legislation.

But beyond the formal organisation, the substance of the work has been individual volunteers: consumers who travelled to state capitols to testify, doctors and pharmacists who submitted clinical perspectives, family members of people who use kratom themselves. The 2016 DEA reversal didn’t happen because of a slick lobbying campaign — it happened because thousands of individuals contacted their representatives within a short window.

Several specific researchers have been visible and credible voices on the science side, contributing peer-reviewed work that’s been cited in regulatory deliberations. Their work is referenced throughout our scientific literature library.

What’s still in motion

Several open questions:

  • Federal regulation. Federal status remains unresolved. Periodic FDA statements warn against kratom use; federal agencies have not pursued scheduling, and the regulatory gap continues. Federal-level KCPA legislation has been proposed but not enacted.
  • Synthetic and isolated alkaloid products. The market has seen the emergence of products containing isolated 7-hydroxymitragynine or synthetic kratom alkaloids. These are pharmacologically distinct from leaf and have produced concerning safety signals. Some KCPA-style legislation explicitly addresses these; the regulatory conversation is active.
  • Local bans. Several large cities continue to ban kratom even within KCPA states. Local advocacy work continues.
  • International trade. Thailand’s 2021 legalisation has reshaped supply-chain options. Indonesia’s position continues to evolve. The export side of the conversation is increasingly part of the policy picture.

Why this story matters

If you use kratom — or sell kratom, or are simply interested in how drug policy actually changes — the past decade has been a working example of consumer-driven regulatory development. It hasn’t been clean. Vendors who didn’t want testing requirements have lobbied against KCPAs. Some advocacy groups have had internal disagreements. State legislative sessions have produced both wins and setbacks.

The point is that the legal availability of kratom in the United States today is not the result of regulatory inaction. It’s the result of sustained, unglamorous work by a lot of individuals over a decade. The same applies to the quality bar in the industry — the GMP standards, the testing expectations, the AKA Qualified Vendor list. These exist because people built them.